Comprehensive analysis identifies novel targets of gemcitabine to improve chemotherapy treatment strategies for colorectal cancer

BACKGROUND: Gemcitabine (GEM) is a second-line anticancer drug of choice for some colorectal cancer (CRC) patients, and GEM inability to be commonly available in the clinic due to the lack of clarity of the exact action targets. METHODS: The half maximal inhibitory concentration (IC50) of GEM treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xinxin, Sun, Liyue, Ling, Xiaomei, Jiang, Yuying, Shen, Ju, Liang, Lei, Zhang, Xuhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471186/
https://www.ncbi.nlm.nih.gov/pubmed/37664836
http://dx.doi.org/10.3389/fendo.2023.1170526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471186/
https://www.ncbi.nlm.nih.gov/pubmed/37664836
http://dx.doi.org/10.3389/fendo.2023.1170526

Ejemplares similares